ORAL VERSUS SUBCUTANEOUS METHOTREXATE IN PEDIATRIC CROHN'S DISEASE: A MULTICENTER PROPENSITY SCORE STUDY

(1) Shaare Zedek Medical Center, Jerusalem, Israel, Jerusalem, Israel;shaare Zedek Medical Center, Jerusalem, Israel, Jerusalem, Israel

(2) Technion Institute, Haifa, Israel

(3) University Of Edinburgh, Edinburgh, United Kingdom

(4) Chop, Philadephia, United States

(5) Boston's Children Hospital, Boston, United States

(6) Montreal, Montreal, Canada

(7) Chop, Philadelphia, United States

(8) Wolfson Hospital, Holon, Israel

(9) Carmel Hospital, Haifa, Israel

(10) Boston Children's Hospital, Boston, United States

(11) Hsc, Toronto, Canada



This item was part of the Best use of immunosuppressants in IBD session at UEG Week 2014

This item can be cited as: United European Gastroenterology Journal; 2014: 2 (Supplement 1)

You may be interested in:

Acute severe colitis in children
English, Presentation, 2015, IBD, Young GI Track
ORAL VERSUS SUBCUTANEOUS METHOTREXATE IN PEDIATRIC CROHN'S DISEASE: A MULTICENTER PROPENSITY SCORE STUDY
Presentation, 2014, Basic & Translational Science, Intestinal & Motility

Categorisation:

  • Format
    • Abstract
  • Year
    • 2014